P/Q-type calcium channel modulators

British Journal of Pharmacology

Volumn 167, Issue 4, 2012, Pages 741-759

  Nimmrich, V ^a   Gross, G ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

calcium antagonists; calcium channels; drug discovery; high throughput screen; ion channels; peptide toxins

Indexed keywords

AMLODIPINE; ANTAZOLINE; CALCICLUDINE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CILNIDIPINE; DILTIAZEM; DODECYLAMINE; DW 13 3; ELIPRODIL; ETIRACETAM; FLUSPIRILENE; GABAPENTIN; HALOTHANE; ISOPRENALINE; KURTOXIN; MEPIRODIPINE; NIFEDIPINE; OMEGA AGATOXIN; OMEGA AGATOXIN IVA; OMEGA AGATOXIN IVB; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; OMEGA CONOTOXIN MVIIC; PHONETOXIN IIA; SNX 482; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ALZHEIMER DISEASE; ANGINA PECTORIS; ASTHMA; ATAXIA; BLOOD PRESSURE; BRADYCARDIA; CACNA1A GNE; CALCIUM CURRENT; CHANNEL GATING; CHRONIC PAIN; DISEASE ASSOCIATION; DIZZINESS; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; EPILEPSY; EXPERIMENTAL MODEL; GENE; GENE MUTATION; HEART ARRHYTHMIA; HEART BLOCK; HUMAN; HYPERTENSION; IN VITRO STUDY; MEDICAL LITERATURE; MEMORY DISORDER; MIGRAINE; MOLECULAR WEIGHT; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SPEECH DISORDER; VASODILATATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, P-TYPE; CALCIUM CHANNELS, Q-TYPE; HUMANS; TOXINS, BIOLOGICAL;

EID: 84867002896     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02069.x     Document Type: Review

References (203)

1. Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, et al,. (2010). Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther 334: 545-555.
2. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I, (2009). Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12: 1567-1576.
3. Adams ME, (2004). Agatoxins: ion channel specific toxins from the American funnel web spider, Agelenopsis aperta. Toxicon 43: 509-525.
4. Adams ME, Mintz IM, Reily MD, Thanabal V, Bean BP, (1993). Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels. Mol Pharmacol 44: 681-688.
5. Ahlquist RP, (1976). Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J 92: 661-664.
6. Aldoss IT, Tashi T, Ganti AK, (2009). Seliciclib in malignancies. Expert Opin Investig Drugs 18: 1957-1965.
7. Amenta F, Lanari A, Mignini F, Silvestrelli G, Traini E, Tomassoni D, (2009). Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. J Neurol Sci 283: 219-223.
8. Amery WK, (1983). Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 23: 70-74.
9. Arroyo G, Aldea M, Fuentealba J, Albillos A, García AG, (2003). SNX482 selectively blocks P/Q Ca2+ channels and delays the inactivation of Na+ channels of chromaffin cells. Eur J Pharmacol 475: 11-18.
10. Asakura K, Matsuo Y, Kanemasa T, Ninomiya M, (1997). P/Q-type Ca2+ channel blocker omega-agatoxin IVA protects against brain injury after focal ischemia in rats. Brain Res 776: 140-145.
11. Asakura K, Kanemasa T, Minagawa K, Kagawa K, Ninomiya M, (1999). The nonpeptide alpha-eudexp6l from Juniperus virginiana Linn. (Cupressaceae) inhibits omega-agatoxin IVA-sensitive Ca2+ currents and synaptosomal 45Ca2+ uptake. Brain Res 823: 169-176.
12. Baell JB, Duggan PJ, Forsyth SA, Lewis RJ, Lok YP, Schroeder CI, (2004). Synthesis and biological evaluation of nonpeptide mimetics of omega-conotoxin GVIA. Bioorg Med Chem 12: 4025-4037.
13. Bayer K, Ahmadi S, Zeilhofer HU, (2004). Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology 46: 743-749.
14. Beedle AM, Zamponi GW, (2000). Block of voltage-dependent calcium channels by aliphatic monoamines. Biophys J 79: 260-270.
15. Benquet P, Guen JL, Dayanithi G, Pichon Y, Tiaho F, (1999). omega-AgaIVA-sensitive (P/Q-type) and -resistant (R-type) high-voltage-activated Ba(2+) currents in embryonic cockroach brain neurons. J Neurophysiol 82: 2284-2293.
16. Biton B, Granger P, Carreau A, Depoortere H, Scatton B, Avenet P, (1994). The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca2+ channels in rat cultured cortical neurons. Eur J Pharmacol 257: 297-301.
17. Biton B, Granger P, Depoortere H, Scatton B, Avenet P, (1995). Block of P-type Ca2+ channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells. Eur J Pharmacol 294: 91-100.
18. Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, Monteil A, et al,. (1999). Splicing of alpha 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nat Neurosci 2: 407-415.
19. Bourinet E, Stotz SC, Spaetgens RL, Dayanithi G, Lemos J, Nargeot J, et al,. (2001). Interaction of SNX482 with domains III and IV inhibits activation gating of alpha(1E) (Ca(V)2.3) calcium channels. Biophys J 81: 79-88.
20. Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, et al,. (1996). Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol 119: 195-204.
21. Brown EM, Fedak SA, Woodard CJ, Aurbach GD, (1976). Beta-Adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity. J Biol Chem 251: 1239-1246.
22. Buraei Z, Elmslie KS, (2008). The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels. J Neurochem 105: 1450-1461.
23. Buraei Z, Schofield G, Elmslie KS, (2006). Roscovitine differentially affects CaV2 and Kv channels by binding to the open state. Neuropharmacology 52: 883-894.
24. Cassola AC, Jaffe H, Fales HM, Afeche SC, Magnoli F, Cipolla-Neto J, (1998). Iω-Phonetoxin-IIA: a calcium channel blocker from the spider Phoneutria nigriventer. Pflugers Arch 436: 545-552.
25. Chen G, Henter ID, Manji HK, (2010). Presynaptic glutamatergic dysfunction in bipolar disorder. Biol Psychiatry 67: 1007-1009.
26. Cho S, Meriney SD, (2006). The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur J Neurosci 23: 3200-3208.
27. Clark RJ, Fischer H, Dempster L, Daly NL, Rosengren KJ, Nevin ST, et al,. (2005). Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. Proc Natl Acad Sci U S A 102: 13767-13772.
28. Craik DJ, Adams DJ, (2007). Chemical modification of conotoxins to improve stability and activity. ACS Chem Biol 2: 457-468.
29. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M, (1993). Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 43: 301-305.
30. Cumbo E, Ligori LD, (2010). Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav 17: 461-466.
31. Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS, (2004). Dual effects of abapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 20: 1566-1576.
32. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A, (2000). Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 151: 145-148.
33. Diener HC, Rahlfs VW, Danesch U, (2004). The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 51: 89-97.
34. Diochot S, Richard S, Baldy-Moulinier M, Nargeot J, Valmier J, (1995). Dihydropyridines, phenylalkylamines and benzothiazepines block N-, P/Q- and R-type calcium currents. Pflugers Arch 431: 10-19.
35. Dobrev D, Milde AS, Andreas K, Ravens U, (1999). The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. Br J Pharmacol 127: 576-582.
36. Dolphin AC, (2009). Calcium channel diversity: multiple roles of calcium channel subunits. Curr Opin Neurobiol 19: 1-8.
37. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ, (2002). Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 45: 171-190.
38. Dos Santos RG, Van Renterghem C, Martin-Moutot N, Mansuelle P, Cordeiro MN, Diniz CR, et al,. (2002). Phoneutria nigriventer omega-phonetoxin IIA blocks the Cav2 family of calcium channels and interacts with omega-conotoxin-binding sites. J Biol Chem 277: 13856-13862.
39. Eastwood SL, Harrison PJ, (2010). Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 67: 1010-1016.
40. Elger CE, Schmidt D, (2008). Modern management of epilepsy: a practical approach. Epilepsy Behav 12: 501-539.
41. Ellis DJ, Dissanayake S, McGuire D, Charapata SG, Staats PS, Wallace MS, et al,. (2008). Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. Neuromodulation 11: 40-49.
42. Enyeart JJ, Biagi BA, Mlinar B, (1992). Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. Mol Pharmacol 42: 364-372.
43. Ertel EA, Smith MM, Leibowitz MD, Cohen CJ, (1994). Isolation of myocardial L-type calcium channel gating currents with the spider toxin omega-Aga-IIIA. J Gen Physiol 103: 731-753.
44. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al,. (2002). Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42: 229-236.
45. Fleckenstein-Grün G, (1994). Historical development of calcium antagonism- in memoriam Albrecht Fleckenstein. High Blood Press 3: 284-290.
46. Fletcher CF, Lutz CM, O'Sullivan TN, Shaughnessy JD Jr, Hawkes R, Frankel WN, et al,. (1996). Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87: 607-617.
47. Fletcher CF, Tottene A, Lennon VA, Wilson SM, Dubel SJ, Paylor R, et al,. (2001). Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J 15: 1288-1290.
48. Freir DB, Costello DA, Herron CE, (2003). A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J Neurophysiol 89: 3061-3069.
49. Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K, (1997). Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 280: 1184-1191.
50. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, et al,. (1997). Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol 121: 1136-1140.
51. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T, (1999). Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 291: 464-473.
52. Galizzi JP, Fosset M, Romey G, Laduron P, Lazdunski M, (1986). Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. Proc Natl Acad Sci U S A 83: 7513-7517.
53. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN, (1996). The novel nticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271: 5768-5776.
54. Geer JJ, Dooley DJ, Adams ME, (1993). K(+)-stimulated 45Ca2+ flux into rat neocortical mini-slices is blocked by omega-Aga-IVA and the dual Na+/Ca2+ channel blockers lidoflazine and flunarizine. Neurosci Lett 158: 97-100.
55. Glasser SP, (1998). The relevance of T-type calcium antagonists: a profile of mibefradil. J Clin Pharmacol 38: 659-669.
56. Gould RJ, Murphy KM, Reynolds IJ, Snyder SH, (1983). Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A 80: 5122-5125.
57. Grobe-Einsler R, Traber J, (1992). Clinical results with nimodipine in Alzheimer disease. Clin Neuropharmacol 15 (Suppl. 1): 416A-417A.
58. Haack JA, Kinser P, Yoshikami D, Olivera BM, (1993). Biotinylated derivatives of omega-conotoxins GVIA and MVIID: probes for neuronal calcium channels. Neuropharmacology 32: 1151-1159.
59. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al,. (2001). Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98: 4687-4692.
60. Han TS, Teichert RW, Olivera BM, Bulaj G, (2008). Conus venoms-a rich source of peptide-based therapeutics. Curr Pharm Des 14: 2462-2479.
61. 1A-containing high-voltage-activated calcium channels. Biophys J 76: 1384-1400.
62. Haria M, Wagstaff AJ, (1995). Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 50: 560-586.
63. He LM, Chen LY, Lou XL, Qu AL, Zhou Z, Xu T, (2002). Evaluation of beta-amyloid peptide 25-35 on calcium homeostasis in cultured rat dorsal root ganglion neurons. Brain Res 939: 65-75.
64. Heinke B, Balzer E, Sandkühler J, (2004). Pre- and postsynaptic contributions of voltage-dependent Ca2+ channels to nociceptive transmission in rat spinal lamina I neurons. Eur J Neurosci 19: 103-111.
65. Hillyard DR, Monje VD, Mintz IM, Bean BP, Nadasdi L, Ramachandran J, et al,. (1992). A new Conus peptide ligand for mammalian presynaptic Ca2+ channels. Neuron 9: 69-77.
66. Hockerman GH, Dilmac N, Scheuer T, Catterall WA, (2000). Molecular determinants ofdiltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels. Mol Pharmacol 58: 1264-1270.
67. Hoffmann U, Dileköz E, Kudo C, Ayata C, (2010). Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab 30: 1588-1592.
68. Horak S, Koschak A, Stuppner H, Striessnig J, (2009). Use-dependent block of voltage-gated Cav2.1 Ca2+ channels by petasins and eudesmol isomers. J Pharmacol Exp Ther 330: 220-226.
69. Hu LY, Ryder TR, Rafferty MF, Taylor CP, Feng MR, et al,. (2000). The discovery of [1-(4-dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)- phen yl]-(3-methyl-but-2-enyl)-amine, an N-type Ca+2 channel blocker with oral activity for analgesia. Bioorg Med Chem 8: 1203-1212.
70. Huang CC, Hsu KS, Gean PW, (1996). Isoproterenol potentiates synaptic transmission primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium channels in the rat amygdala. J Neurosci 16: 1026-1033.
71. Huang CC, Wang SJ, Gean PW, (1998). Selective enhancement of P-type calcium currents by isoproterenol in the rat amygdala. J Neurosci 18: 2276-2282.
72. Ishibashi H, Yatani A, Akaike N, (1995). Block of P-type Ca2+ channels in freshly dissociated rat cerebellar Purkinje neurons by diltiazem and verapamil. Brain Res 695: 88-91.
73. Ishikawa T, Kaneko M, Shin HS, Takahashi T, (2005). Presynaptic N-type and P/Q-type Ca2+ channels mediating synaptic transmission at the calyx of Held of mice. J Physiol 568: 199-209.
74. Jones MV, Brooks PA, Harrison NL, (1992). Enhancement of gamma-aminobutyric acid-activated Cl- currents in cultured rat hippocampal neurones by three volatile anaesthetics. J Physiol 449: 279-293.
75. Jun K, Piedras-Rentería ES, Smith SM, Wheeler DB, Lee SB, Lee TG, et al,. (1999). Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. Proc Natl Acad Sci U S A 96: 15245-15250.
76. Kamatchi GL, Chan CK, Snutch T, Durieux ME, Lynch C 3rd, (1999). Volatile anesthetic inhibition of neuronal Ca channel currents expressed in Xenopus oocytes. Brain Res 831: 85-96.
77. Kameyama K, Aono K, Kitamura K, (1999). Isoflurane inhibits neuronal Ca2+ channels through enhancement of current inactivation. Br J Anaesth 82: 402-411.
78. Kang MG, Felix R, Campbell KP, (2002). Long-term regulation of voltage-gated Ca(2+) channels by gabapentin. FEBS Lett 528: 177-182.
79. Kass RS, (1987). Voltage-dependent modulation of cardiac calcium channel current by optical isomers of Bay K 8644: implications for channel gating. Circ Res 61: I1-I5.
80. Khosravani H, Zamponi GW, (2006). Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol Rev 86: 941-966.
81. Kim JI, Takahashi M, Ogura A, Kohno T, Kudo Y, Sato K, (1994). Hydroxyl group of Tyr13 is essential for the activity of omega-conotoxin GVIA, a peptide toxin for N-type calcium channel. J Biol Chem 269: 23876-23878.
82. Kim JI, Konishi S, Iwai H, Kohno T, Gouda H, Shimada I, et al,. (1995). Three-dimensional solution structure of the calcium channel antagonist omega-agatoxin IVA: consensus molecular folding of calcium channel blockers. J Mol Biol 250: 659-671.
83. Kisilevsky AE, Zamponi GW, (2008). Presynaptic calcium channels: structure, regulators, and blockers. Handb Exp Pharmacol 184: 45-75.
84. Knierim E, Leisle L, Wagner C, Weschke B, Lucke B, Bohner G, et al,. (2011). Recurrent stroke due to a novel voltage sensor mutation in Cav2.1 responds to verapamil. Stroke 42: e14-e17.
85. Koch ED, Olivera BM, Terlau H, Conti F, (2004). The binding of kappa-Conotoxin PVIIA and fast C-type inactivation of Shaker K+ channels are mutually exclusive. Biophys J 86: 191-209.
86. Kokubo H, Kayed R, Glabe CG, Yamaguchi H, (2005). Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res 1031: 222-228.
87. Krnjević K, (1992). Cellular and synaptic actions of general anaesthetics. Gen Pharmacol 23: 965-975.
88. Kunkler PE, Kraig RP, (2004). P/Q Ca2+ channel blockade stops spreading depression and related pyramidal neuronal Ca2+ rise in hippocampal organ culture. Hippocampus 14: 356-367.
89. Lampe RA, Defeo PA, Davison MD, Young J, Herman JL, Spreen RC, et al,. (1993). Isolation and pharmacological characterization of omega-grammotoxin SIA, a novel peptide inhibitor of neuronal voltage-sensitive calcium channel responses. Mol Pharmacol 44: 451-460.
90. Leão RM, Cruz JS, Diniz CR, Cordeiro MN, Beirão PS, (2000). Inhibition of neuronal high-voltage activated calcium channels by the omega-phoneutria nigriventer Tx3-3 peptide toxin. Neuropharmacology 39: 1756-1767.
91. Lee CY, Chen CC, Liou HH, (2009). Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol 158: 1753-1762.
92. Levy NA, Janicak PG, (2000). Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord 2: 108-119.
93. Lewis RJ, Dutertre S, Vetter I, Christie MJ, (2012). Conus venom Peptide pharmacology. Pharmacol Rev 64: 259-298.
94. Liau CS, (2005). Barnidipine: a new calcium channel blocker for hypertension treatment. Expert Rev Cardiovasc Ther 3: 207-213.
95. Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A, (2004). Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63: 2240-2244.
96. Li-Smerin Y, Hackos DH, Swartz KJ, (2000). alpha-helical structural elements within the voltage-sensing domains of a K(+) channel. J Gen Physiol 115: 33-50.
97. Llinás R, Sugimori M, Lin JW, Cherksey B, (1989). Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison. Proc Natl Acad Sci U S A 86: 1689-1693.
98. López-Arrieta JM, Birks J, (2002). Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev (3): CD000147.
99. Lu CW, Lin TY, Wang SJ, (2010). Memantine depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase C in rat cerebralcortex nerve terminals: an NMDA receptor-independent mechanism. Neurochem Int 57: 168-176.
100. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al,. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101: 9861-9866.
101. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T, et al,. (2004). A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 41: 701-710.
102. MacManus A, Ramsden M, Murray M, Henderson Z, Pearson HA, Campbell VA, (2000). Enhancement of (45)Ca(2+) influx and voltage-dependent Ca(2+) channel activity by beta-amyloid-(1-40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. J Biol Chem 275: 4713-4718.
103. Mansvelder HD, Stoof JC, Kits KS, (1996). Dihydropyridine block of omega-agatoxin IVA- and omega-conotoxin GVIA-sensitive Ca2+ channels in rat pituitary melanotropic cells. Eur J Pharmacol 311: 293-304.
104. Markley HG, Cheronis JC, Piepho RW, (1984). Verapamil in prophylactic therapy of migraine. Neurology 34: 973-976.
105. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al,. (2001). Efficacy of gabapentin in migraine prophylaxis. Headache 41: 119-128.
106. Mathews EA, García E, Santi CM, Mullen GP, Thacker C, Moerman DG, et al,. (2003). Critical residues of the Caenorhabditis elegans unc-2 voltage-gated calcium channel that affect behavioral and physiological properties. J Neurosci 23: 6537-6545.
107. McAuley BJ, Schroeder JS, (1982). The use of diltiazem hydrochloride in cardiovascular disorders. Pharmacotherapy 2: 121-133.
108. McDonough SI, Swartz KJ, Mintz IM, Boland LM, Bean BP, (1996). Inhibition of calcium channels in rat central and peripheral neurons by omega-conotoxin MVIIC. J Neurosci 16: 2612-2623.
109. McDonough SI, Lampe RA, Keith RA, Bean BP, (1997). Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA. Mol Pharmacol 52: 1095-1104.
110. McDonough SI, Boland LM, Mintz IM, Bean BP, (2002). Interactions among toxins that inhibit N-type and P-type calcium channels. J Gen Physiol 119: 313-328.
111. McNaughton NCL, Horridge E, Gleave R, Beswick PJ, Chen YH, Powell AJ, et al,. (2008). Piperazine amide calcium canne blockers such as NMED-160 block Cav2.2, Cav3.2 and Cav1.2 human recombinant calcium channels in both a tonic and use-dependent manner. FENS Abstr. 4, 124.24.
112. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al,. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536.
113. Menzler S, Bikker JA, Suman-Chauhan N, Horwell DC, (2000). Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA. Bioorg Med Chem Lett 10: 345-347.
114. Mezler M, Barghorn S, Schoemaker H, Gross G, Nimmrich V, (2012a). Aβ oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes. Br J Pharmacol 165: 1572-1583.
115. Mezler M, Hermann D, Swensen AM, Draguhn A, Terstappen GC, Gross G, et al,. (2012b). Development and validation of a fluorescence-based HTS assay for the identification of P/Q-type calcium channel blockers. Comb Chem High Throughput Screen 15: 372-385.
116. Milhaud D, Fagni L, Bockaert J, Lafon-Cazal M, (2002). Inhibition of voltage-gated Ca2+ channels by antazoline. Neuroreport 13: 1711-1714.
117. Mintz IM, Venema VJ, Adams ME, Bean BP, (1991). Inhibition of N- and L-type Ca2+ channels by the spider venom toxin omega-Aga-IIIA. Proc Natl Acad Sci U S A 88: 6628-6631.
118. Mintz IM, Venema VJ, Swiderek KM, Lee TD, Bean BP, Adams ME, (1992a). P-type calcium channels blocked by the spider toxin omega-Aga-IVA. Nature 355: 827-829.
119. Mintz IM, Adams ME, Bean BP, (1992b). P-type calcium channels in rat central and peripheral neurons. Neuron 9: 85-95.
120. Monaco EA 3rd, Vallano ML, (2005). Roscovitine triggers excitotoxicity in cultured granule neurons by enhancing glutamate release. Mol Pharmacol 68: 1331-1342.
121. Motin L, Yasuda T, Schroeder CI, Lewis RJ, Adams DJ, (2007). Omega-conotoxin CVIB differentially inhibits native and recombinant N- and P/Q-type calcium channels. Eur J Neurosci 25: 435-444.
122. Nadasdi L, Yamashiro D, Chung D, Tarczy-Hornoch K, Adriaenssens P, Ramachandran J, (1995). Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry 34: 8076-8081.
123. Nebe J, Vanegas H, Neugebauer V, Schaible HG, (1997). Omega-agatoxin IVA, a P-type calcium channel antagonist, reduces nociceptive processing in spinal cord neurons with input from the inflamed but not from the normal knee joint-an electrophysiological study in the rat in vivo. Eur J Neurosci 9: 2193-2201.
124. Nielsen KJ, Adams DA, Alewood PF, Lewis RJ, Thomas L, Schroeder T, (1999a). Effects of chirality at Tyr13 on the structure-activity relationships of omega-conotoxins from Conus magus. Biochemistry 38: 6741-6751.
125. Nielsen KJ, Adams D, Thomas L, Bond T, Alewood PF, Craik DJ, et al,. (1999b). Structure-activity relationships of omega-conotoxins MVIIA, MVIIC and 14 loop splice hybrids at N and P/Q-type calcium channels. J Mol Biol 289: 1405-1421.
126. Niespodziany I, Klitgaard H, Margineanu DG, (2001). Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 306: 5-8.
127. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, et al,. (2009). Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem 284: 32895-32905.
128. Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T, (2003a). A comparison of Ca2+ channel blocking mode between gabapentin and verapamil: implication for protection against hypoxic injury in rat cerebrocortical slices. Br J Pharmacol 139: 435-443.
129. Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T, (2003b). Gabapentin blocks L-type and P/Q-type Ca2+ channels involved in depolarization-stimulated nitric oxide synthase activity in primary cultures of neurons from mouse cerebral cortex. Pharm Res 20: 897-899.
130. O'Neill MJ, Hicks CA, Ward MA, Osborne DJ, Wishart G, Mathews KS, et al,. (2001). LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia. Brain Res 888: 138-149.
131. Ophoff RA, Terwindt GM, Frants RR, Ferrari MD, (1998). P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy. Trends Pharmacol Sci 19: 121-127.
132. Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, et al,. (1998). Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 18: 404-413.
133. Pepine CJ, Lambert CR, (1990). Cardiovascular effects of nicardipine. Angiology 41: 978-986.
134. Pexton T, Moeller-Bertram T, Schilling JM, Wallace MS, (2011). Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert Opin Investig Drugs 20: 1277-1284.
135. Pietrobon D, (2002). Calcium channels and channelopathies of the central nervous system. Mol Neurobiol 25: 31-50.
136. Pietrobon D, (2010). Cav2.1 channelopathies. Eur J Physiol 460: 375-393.
137. Pisani A, Bonsi P, Martella G, De Persis C, Costa C, Pisani F, et al,. (2004). Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 45: 719-728.
138. Pizza V, Busillo V, Agresta A, Bisogno A, Capasso A, (2011). Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem 11: 31-34.
139. Plomp JJ, van den Maagdenberg AM, Molenaar PC, Frants RR, Ferrari MD, (2001). Mutant. P/Q-type calcium channel electrophysiology and migraine. Curr Opin Investig Drugs 2: 1250-1260.
140. Pluzhnikov K, Vassilevski A, Korolkova Y, Fisyunov A, Iegorova O, Krishtal O, et al,. (2007). omega-Lsp-IA, a novel modulator of P-type Ca2+ channels. Toxicon 50: 993-1004.
141. Popović M, Popović N, Jovanova-Nesić K, Bokonjić D, Dobrić S, Rosić N, (1997). Open field behavior in nucleus basalis magnocellularis-lesioned rats treated with physostigmine and verapamil. Int J Neurosci 91: 181-188.
142. Qian J, Noebels JL, (2001). Presynaptic Ca2+ channels and neurotransmitter release at the terminal of a mouse cortical neuron. J Neurosci 21: 3721-3728.
143. Qin N, Olcese R, Stefani E, Birnbaumer L, (1998). Modulation of human neuronal alpha 1E-type calcium channel by alpha 2 delta-subunit. Am J Physiol 274: C1324-C1331.
144. Rajakulendran S, Kaski D, Hanna MG, (2012). Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. Nat Rev Neurol 8: 86-96.
145. Ramsden M, Henderson Z, Pearson HA, (2002). Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status. Brain Res 956: 254-261.
146. Randall A, Tsien RW, (1995). Pharmacological dissection of multiple types of Ca2+ channel currents in rat cerebellar granule neurons. J Neurosci 15: 2995-3012.
147. Rehberg B, Xiao YH, Duch DS, (1996). Central nervous system sodium channels are significantly suppressed at clinical concentrations of volatile anesthetics. Anesthesiology 84: 1223-1233.
148. Rogawski MA, Löscher W, (2004). The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5: 553-564.
149. Rogawski MA, Wenk GL, (2003). The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 9: 275-308.
150. Rogers JC, Qu Y, Tanada TN, Scheuer T, Catterall WA, (1996). Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel alpha subunit. J Biol Chem 271: 15950-15962.
151. Rosen MR, Wit AL, Hoffman BF, (1975). Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am Heart J 89: 665-673.
152. Rovira C, Arbez N, Mariani J, (2002). Abeta(25-35) and Abeta(1-40) act on different calcium channels in CA1 hippocampal neurons. Biochem Biophys Res Commun 296: 1317-1321.
153. Sah DW, Bean BP, (1994). Inhibition of P-type and N-type calcium channels by dopamine receptor antagonists. Mol Pharmacol 45: 84-92.
154. Sather WA, Tanabe T, Zhang JF, Mori Y, Adams ME, Tsien RW, (1993). Distinctive biophysical and pharmacological properties of class A (BI) calcium channel alpha 1 subunits. Neuron 11: 291-303.
155. Sato K, Park NG, Kohno T, Maeda T, Kim JI, Kato R, et al,. (1993). Role of basic residues for the binding of omega-conotoxin GVIA to N-type calcium channels. Biochem Biophys Res Commun 194: 1292-1296.
156. Schlame M, Hemmings HC Jr, (1995). Inhibition by volatile anesthetics of endogenous glutamate release from synaptosomes by a presynaptic mechanism. Anesthesiology 82: 1406-1416.
157. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G, (2010). Ziconotide for treatment of severe chronic pain. Lancet 375: 1569-1577.
158. Scholz H, (1997). Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 10 (Suppl. 3): 869-872.
159. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al,. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
160. Schweitz H, Heurteaux C, Bois P, Moinier D, Romey G, Lazdunski M, (1994). Calcicludine, a venom peptide of the Kunitz-type protease inhibitor family, is a potent blocker of high-threshold Ca2+ channels with a high affinity for L-type channels in cerebellar granule neurons. Proc Natl Acad Sci U S A 91: 878-882.
161. Scott VE, Vortherms TA, Niforatos W, Swensen AM, Neelands T, Milicic I, et al,. (2012). A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. Biochem Pharmacol 83: 406-418.
162. Sidach SS, Mintz IM, (2002). Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels. J Neurosci 22: 2023-2034.
163. Sills GJ, (2006). The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6: 108-113.
164. Sitges M, Guarneros A, Nekrassov V, (2007). Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacology 53: 854-862.
165. Small DL, Monette R, Mealing G, Buchan AM, Morley P, (1995). Neuroprotective effects of omega-Aga-IVA against in vitro ischaemia in the rat hippocampal slice. Neuroreport 6: 1617-1620.
166. Solem M, McMahon T, Messing RO, (1997). Protein kinase A regulates regulates inhibition of N- and P/Q-type calcium channels by ethanol in PC12 cells. J Pharmacol Exp Ther 282: 1487-1495.
167. Solomon GD, Steel JG, Spaccavento LJ, (1983). Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 250: 2500-2502.
168. Soong TW, DeMaria CD, Alvania RS, Zweifel LS, Liang MC, Mittman S, et al,. (2002). Systematic identification of splice variants in human P/Q-type channel alpha1(2.1) subunits: implications for current density and Ca2+-dependent inactivation. J Neurosci 22: 10142-10152.
169. Stea A, Tomlinson WJ, Soong TW, Bourinet E, Dubel SJ, Vincent SR, et al,. (1994). Localization and functional properties of a rat brain alpha 1A calcium channel reflect similarities to neuronal Q- and P-type channels. Proc Natl Acad Sci U S A 91: 10576-10580.
170. Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P, (1995). Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 36: 997-1002.
171. Stefani A, Spadoni F, Siniscalchi A, Bernardi G, (1996a). Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307: 113-116.
172. Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G, (1996b). Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 277: 121-127.
173. Stefani A, Spadoni F, Bernardi G, (1997). Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147: 115-122.
174. Stotz SC, Spaetgens RL, Zamponi GW, (2000). Block of voltage-dependent calcium channel by the green mamba toxin calcicludine. J Membr Biol 174: 157-165.
175. Striano P, Striano S, (2008). Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today 44: 353-368.
176. Study RE, (1994). Isoflurane inhibits multiple voltage-gated calcium currents in hippocampal pyramidal neurons. Anesthesiology 81: 104-116.
177. Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN, (1993). Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 244: 293-301.
178. Sutton KG, Siok C, Stea A, Zamponi GW, Heck SD, Volkmann RA, et al,. (1998). Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3. Mol Pharmacol 54: 407-418.
179. Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH, (2002). Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 135: 257-265.
180. Takeuchi K, Park E, Lee C, Kim J, Takahashi H, Swartz K, et al,. (2002). Solution structure of omega-grammotoxin SIA, a gating modifier of P/Q and N-type Ca(2+) channel. J Mol Biol 321: 517-526.
181. Terlau H, Olivera BM, (2004). Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol Rev 84: 41-68.
182. Tollefson GD, (1990). Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 27: 1133-1142.
183. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F, (2008). Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 30: 744-766.
184. Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, Santello M, et al,. (2009). Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. Neuron 61: 762-773.
185. Tottene A, Urbani A, Pietrobon D, (2011). Role of different voltage-gated Ca2+ channels in cortical spreading depression: specific requirement of P/Q-type Ca2+ channels. Channels (Austin) 5: 110-114.
186. Trepakova ES, Dech SJ, Salata JJ, (2006). Flunarizine is a highly potent inhibitor of cardiac hERG potassium current. J Cardiovasc Pharmacol 47: 211-220.
187. Viana F, Van den Bosch L, Missiaen L, Vandenberghe W, Droogmans G, Nilius B, et al,. (1997). Mibefradil (Ro 40-5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones. Cell Calcium 22: 299-311.
188. Vieira LB, Kushmerick C, Hildebrand ME, Garcia E, Stea A, Cordeiro MN, et al,. (2005). Inhibition of high voltage-activated calcium channels by spider toxin PnTx3-6. J Pharmacol Exp Ther 314: 1370-1377.
189. Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK, (2010). Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc) 46: 265-277.
190. Wauquier A, Ashton D, Marrannes R, (1985). The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 5 (Suppl. 2): 119-123.
191. Webster LR, Fisher R, Charapata S, Wallace MS, (2009). Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage 37: 363-372.
192. Wermeling DP, (2005). Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 25: 1084-1094.
193. Winterfield JR, Swartz KJ, (2000). A hot spot for the interaction of gating modifier toxins with voltage-dependent ion channels. J Gen Physiol 116: 637-644.
194. Wu LG, Saggau P, (1995). Block of multiple presynaptic calcium channel types by omega-conotoxin-MVIIC at hippocampal CA3 to CA1 synapses. J Neurophysiol 73: 1965-1972.
195. Yakash TL, (2006). Calcium channels as therapeutic targets in neuropathic pain. J Pain 7: S13-S30.
196. Yamamoto T, Takahara A, (2009). Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 9: 377-395.
197. Yan L, Adams ME, (2000). The spider toxin omega-Aga IIIA defines a high affinity site on neuronal high voltage-activated calcium channels. J Biol Chem 275: 21309-21316.
198. Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P, (2002). Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J Physiol 540: 761-770.
199. Ye Q, Yan LY, Xue LJ, Wang Q, Zhou ZK, Xiao H, et al,. (2011). Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: a possible locus of action in the prevention of migraine. Neurosci Lett 487: 394-399.
200. Yu W, Horowitz SH, (2003). Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 60: 120-121.
201. Zamponi GW, Lory P, Perez-Reyes E, (2010). Role of voltage-gated calcium channels in epilepsy. Pflugers Arch 460: 395-403.
202. Zhu G, Okada M, Murakami T, Kawata Y, Kamata A, Kaneko S, (2002). Interaction between carbamazepine, zonisamide and voltage-sensitive Ca2+ channel on acetylcholine release in rat frontal cortex. Epilepsy Res 49: 49-60.
203. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al,. (1997). Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium cannel. Nat Genet 15: 62-69.